Northeast Pharmaceutical Group Co., Ltd. specializes in the production and marketing of pharmaceutical ingredients and preparations. The group's products include antibiotics, vitamins, cardiovascular treatments, anesthetics, medical plants, etc. China accounts for 86.3% of net sales.

Employees

5,727

Sector

Pharmaceuticals

Calendar

08-25 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
17/08/26	CN¥5.510	+9.98%	82,403,090
17/08/26	CN¥5.010	-0.40%	16,588,266
14/08/26	CN¥5.030	+1.21%	26,294,714
13/08/26	CN¥4.970	+1.22%	36,164,406
12/08/26	CN¥4.910	+1.66%	18,697,009

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. 18/08/2026			5-day change	1st Jan Change
5.510 ^CNY	+9.98%		+15.03%	+5.56%

06-15	Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2025, Payable on 23 June 2026	CI
04-27	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	7.86B 1.17B 1.01B 948M 861M 1.62B 112B 1.64B 11.11B 4.36B 55.88B 4.38B 4.28B 186B	P/E 2024	18.2x	P/E 2025	29x
Enterprise Value	6.37B 945M 816M 768M 698M 1.31B 90.54B 1.33B 9.01B 3.53B 45.28B 3.55B 3.47B 151B	EV / Sales 2024	0.62x	EV / Sales 2025	0.84x
Free-Float	39.51%	Yield 2024	1.9%	Yield 2025	1.05%

06-15	Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2025, Payable on 23 June 2026	CI
04-27	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-02	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-01	Northeast Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 23, 2026	CI
27/10/25	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
09/10/25	Northeast Pharmaceutical Unit Gets Clinical Trial Approval for Glioma Treatment	MT
08/09/25	Northeast Pharmaceutical Appoints CFO	MT
02/09/25	Northeast Pharmaceutical CFO Resigns	MT
26/08/25	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
05/06/25	Northeast Pharmaceutical Gets Nod to Market Antiobiotic in Europe	MT
28/04/25	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25/04/25	Northeast Pharmaceutical Group Co., Ltd. Announces Directorate Appointments	CI
25/04/25	Northeast Pharmaceutical Group Co., Ltd. Approves Cash Dividend on (A Shares) for 2024, Payable on 23 June 2025	CI

1 day	+9.98%
1 week	+15.03%
Current month	+20.31%
1 month	+16.99%
3 months	+12.91%
6 months	+7.41%
Current year	+5.56%

Northeast Pharmaceutical Group Co., Ltd. Share Price

Stocks

000597

CNE0000009G0

Pharmaceuticals

Valuation: Northeast Pharmaceutical Group Co., Ltd.

Chart: Northeast Pharmaceutical Group Co., Ltd.

Latest news : Northeast Pharmaceutical Group Co., Ltd.

Press Releases: Northeast Pharmaceutical Group Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Northeast Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	4.78	5.51
1 month	4.47	5.51
Current year	4.09	5.73
1 year	4.09	5.98
3 years	3.72	6.69
5 years	3.72	9.3
10 years	3.72	9.3

Manager	Title	Age	Since
Yong Gang Cai CEO	Chief Executive Officer	46	20/01/2025
Xin Li DFI	Director of Finance/CFO	46	05/09/2025
Dong Sheng Yan IRC	Investor Relations Contact	42	30/06/2024

Director	Title	Age	Since
Kai Zhou CHM	Chairman	62	20/01/2025
Xin Hua Ao BRD	Director/Board Member	62	17/07/2018
Cheng Ren Huang BRD	Director/Board Member	62	17/07/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/06/22	Zhengwei	Buy		36,000	0.0027%
26/05/22	Yan Liu	Buy	Executive/Senior Manager	100	0.0000%
25/05/22	Zhengwei	Buy		28,100	0.0021%

	2024	2025
Net sales	7.5B 1.11B 961M 904M 822M 1.55B 107B 1.57B 10.61B 4.16B 53.31B 4.18B 4.09B 178B	7.07B 1.05B 906M 853M 775M 1.46B 101B 1.48B 10B 3.92B 50.27B 3.94B 3.85B 167B
Net income	410M 60.78M 52.49M 49.39M 44.89M 84.43M 5.82B 85.66M 579M 227M 2.91B 228M 223M 9.7B	260M 38.57M 33.31M 31.34M 28.48M 53.57M 3.7B 54.36M 368M 144M 1.85B 145M 142M 6.16B
Net Debt	-2.88B -426M -368M -347M -315M -592M -40.86B -601M -4.06B -1.59B -20.44B -1.6B -1.57B -68.07B	-1.49B -221M -191M -180M -163M -307M -21.18B -312M -2.11B -826M -10.59B -830M -812M -35.28B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHEAST PHARMACEUTICAL GROUP CO., LTD.	+9.98%	+15.03%	-5.81%	+1.10%	1.06B
ELI LILLY AND COMPANY	+3.26%	+0.48%	+74.89%	+123.42%	1,055B
JOHNSON & JOHNSON	+3.23%	+4.18%	+53.56%	+56.91%	632B
ABBVIE INC.	+3.05%	+2.97%	+24.66%	+71.52%	442B
ROCHE HOLDING AG	+1.35%	-2.17%	+40.98%	+41.50%	351B
NOVARTIS AG	+1.75%	-0.24%	+25.28%	+40.46%	290B
ASTRAZENECA PLC	+2.13%	-0.32%	+0.58%	+10.77%	243B
AMGEN INC.	+1.64%	+2.92%	+45.72%	+62.86%	227B
NOVO NORDISK A/S	+1.35%	-3.53%	-14.72%	-52.63%	200B
GILEAD SCIENCES, INC.	+3.06%	+5.47%	+21.36%	+88.71%	172B
Average	+3.14%	-0.08%	+26.65%	+44.46%	361.36B
Weighted average by Cap.	+2.70%	-1.87%	+43.37%	+67.99%